

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis.

Authors: Bongiovanni M, Giovanella L, Romanelli F, Trimboli P

Journal: Thyroid : official journal of the American Thyroid Association

Year: 2019 Feb

Issue: 29

Volume: 2

Pages: 222-228

DOI: [10.1089/thy.2018.0394](https://doi.org/10.1089/thy.2018.0394)

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis.

Massimo Bongiovanni¹, MD; Luca Giovanella², MD; Francesco Romanelli³, MD; Pierpaolo Trimboli², MD.

Authors' affiliations:

¹Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, Lausanne, Switzerland.

²Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

³Department of Experimental Medicine, Sapienza University, Rome, Italy.

Authors' full contact information:

Massimo Bongiovanni: Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital. Rue du Bugnon 25, CH-1011, Lausanne, Switzerland. E-mail: massimo.bongiovanni@chuv.ch

Luca Giovanella: Department of Nuclear Medicine and Thyroid Center, Oncology Institute of Southern Switzerland. Via Ospedale 6, CH-6500, Bellinzona, Switzerland. E-mail: luca.giovanella@eoc.ch

Francesco Romanelli: Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy, E-mail: francesco.romanelli@uniroma1.it

Pierpaolo Trimboli: Department of Nuclear Medicine and Thyroid Center, Oncology Institute of Southern Switzerland. Via Ospedale 6, CH-6500, Bellinzona, Switzerland. E-mail: pierpaolo.trimboli@eoc.ch

Thyroid
Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

RUNNING TITLE: NIFTP according to Bethesda system.

KEYWORDS: non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), fine-needle aspiration cytology (FNAC), indeterminate, the Bethesda system for reporting thyroid cytopathology (TBSRTC), thyroid carcinoma.

Abstract

Background.

The recent introduction of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) in the WHO classification of thyroid tumors has significantly modified the risk of malignancy of cytological diagnoses. In fact, while this tumor was previously classified as a carcinoma (the encapsulated, non-invasive form follicular variant of papillary thyroid carcinoma), it is now considered a neoplasm with low malignant potential. Given that the cytological features of NIFTP are not specific and overlap with other pathologic entities, there is no specific cytological diagnostic category for NIFTP. To obtain more robust information about the cytological findings associated with NIFTP, we systematically reviewed published articles and carried out a meta-analysis of the data.

Research Design and Methods.

The review was conducted according to Prisma guidelines. A comprehensive literature search of the PubMed/MEDLINE and Scopus databases was conducted using a combination of terms “non-invasive”, “encapsulated”, “follicular variant”, “NIFTP” and “thyroid cancer”. The search was updated until June 2018, and references of the retrieved articles were also screened. Only original articles reporting the classification of histologically proven NIFTPs with cytological findings according to the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) were eligible for inclusion.

Results.

The literature search revealed 117 articles, of which 15 were included in the study. All studies were retrospective. A total number of 915 NIFTP cases were retrieved. The incidence of cases cytologically classified according to TBSRTC was as follows: non-diagnostic 3%, benign 10%, atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) 30%, follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN) 21%, suspicious for malignancy 24%, and malignant 8%. Mild heterogeneity between the studies was found. Publication bias was absent.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Conclusions.

This meta-analysis shows that the cytological diagnoses associated with NIFTP by fine-needle aspiration cytology includes a wide spectrum of findings. The majority of cases are cytologically indeterminate and the remainders may be read as non-diagnostic, benign or malignant. In order to develop an accurate presurgical diagnosis of these cases, further cytological and/or molecular characteristics need to be identified.

Introduction

The recently reviewed version of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has introduced a modification into each diagnostic category (DC) concerning the risk of malignancy (ROM) (1). In the first edition of TBSRTC, which has received worldwide recognition, each DC had an associated ROM and suggestions were made as to the management and the success rate of treatment of each category (2). In the current edition of the TBSRTC, each DC is associated with two different ROMs: one that takes into consideration the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) as a carcinoma and the other that considers NIFTP as a tumor with low malignant potential (1, 2). The downgrading of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive E-FV-PTC, aka NIFTP) into a tumor with low malignant potential and the deletion of the term carcinoma in its definition, has also forced the committee in charge of the revised version of TBSRTC to downgrade the ROM (2, 3). It needs to be emphasized that the diagnosis of NIFTP requires excision of the lesion and surgical pathology, as a complete histopathological evaluation of the tumor capsule, tumor content and search for vascular invasion can only be carry out with histological evaluation (3). For this reason, TBSRTC does not comprise a specific DC for NIFTP and preliminary data have shown that these tumors are associated with a spectrum of cytological findings, from benign to indeterminate (i.e. Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance (AUS/FLUS) and Follicular Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN)), and from Suspicious for Malignancy (SM) to Malignant (M) (4, 5). Overall, these studies indicate that NIFTP is difficult to distinguish from the non-invasive E-FV-PTC and the infiltrative form of FV-PTC (I-FV-PTC). A predominant microfollicular pattern in the absence of nuclear atypia is mostly associated with a benign diagnosis on histology (either hyperplastic nodule or follicular adenoma) whilst the presence of microcalcifications and papillary structures showing typical nuclear features of PTC with more than 2-3 intra nuclear pseudoinclusions (INI) are mostly associated with a classical variant of PTC (CV-PTC) (6). Identification of the cytological diagnosis under which a NIFTP is most frequently classified, could help better defining the management strategies for the patient preoperatively. Here we aimed to

Thyroid
Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

systematically review the literature on the cytological features of NIFTP to obtain more robust evidence on this topic. Then, based on the retrieved data, we attempted to perform a meta-analysis on the prevalence of NIFTP in the different DCs of TBSRTC.

Material and Methods

Conduct of review

This present systematic review was conducted according to Prisma guidelines [view Supplementary Table 1].

Search strategy

A comprehensive literature search was conducted using the online databases of Pubmed/MEDLINE and Scopus by searching papers reporting NIFTP cases, using a combination of the terms “non-invasive”, “encapsulated”, “follicular variant”, “NIFTP” and “thyroid cancer” to find articles with data on the classification of fine-needle aspiration cytology (FNAC) samples as NIFTP, according to TBSRTC. This allowed identifying a large number of studies that reported histologically proven NIFTP, and which contained information on the presurgical cytological specimens. A beginning date limit was not used. The search was updated until June 8th, 2018 and no language restrictions were used. To try to expand the search, references of the retrieved articles were also screened to identify additional studies.

Study selection

Only original articles reporting NIFTP cases with a histological assessment and a classification of their FNAC samples were initially considered as eligible for inclusion. The main exclusion criteria were articles with overlapping patient or nodule data and case reports; in addition, papers reporting only some TBSRTC categories were excluded because these results did not allow us to know the distribution of NIFTP among the six categories of TBSRTC and calculate the incidence of each cytological class. Two researchers (MB, PT) independently reviewed titles and abstracts of the retrieved articles, applying the selection criteria; then, all authors independently reviewed the full-text of the remaining articles to determine their final inclusion.

Data extraction

For each included study, the following information was extracted independently by two investigators (MB, PT) in a piloted form: 1) study data (authors, year of publication and country of origin); 2) number of cases of NIFTP evaluated; and 3) distribution of NIFTP within TBSRTC categories. Data were cross-checked, and any discrepancies were discussed and mutually solved.

Study quality assessment

The risk of bias of included studies was assessed independently by two reviewers (MB, PT) through the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for the following aspects: patient selection; index test; reference standard; flow and timing. Risk of bias and concerns about applicability were rated as low, high and unclear risk.

Statistical analysis

A proportion meta-analysis calculation was used to obtain the pooled rate of NIFTP assessed in TBSRTC categories. For statistical pooling of data, the DerSimonian and Laird method (random-effects model) was used (7). In this model, pooled data represent weighted averages related to the sample sizes of studies. Pooled data were presented with 95% confidence intervals (95% CI) and displayed using a forest plot. I-square index was used to quantify the heterogeneity among the studies, and significant heterogeneity was defined as an I-square value > 50%. Egger's test was carried out to evaluate the possible presence of a significant publication bias. Statistical analyses were performed using the StatsDirect statistical software version (StatsDirect Ltd; Altrincham, UK).

Results

Eligible articles

The comprehensive literature search identified 117 articles. An initial review of the titles and abstracts excluded 98 articles. A further four articles were excluded because they reported only NIFTP cases which were either FN/SFN or SM on FNAC (8, 9) or did not include the whole spectrum of the Bethesda system categories (6, 10); hence, it was not

possible to calculate the rate of NIFTP within the overall diagnostic categories of FNAC. In the end, fifteen articles (4, 5, 11-23) were included in the study [see Supplemental Figure 1].

Qualitative analysis (systematic review)

Included studies were published by authors from the USA, Canada, Europe and Asia. The majority of these studies reported series of histologically proven NIFTP in which the cytological diagnoses were retrospectively reviewed for the publication; other studies reported NIFTP nodules in which the possibility of a NIFTP lesion had been suggested on cytological evaluation and was then confirmed on histopathology. Only two papers used liquid based cytology. Data on the cytological assessments could be clearly identified in all these manuscripts and the true percentage of each FNAC category was calculated. Table 1 details the main publication characteristics and findings of the included studies. Quality assessment of the studies is reported in Table 2.

Quantitative analysis (meta-analysis)

Overall, the included articles reported 915 histologically proven NIFTP lesions for which a preoperative FNAC was available. The pooled rate of each FNA category is shown in Figure 1 and details of the results are reported in Table 3. In all Bethesda categories there was mild heterogeneity between the studies, while publication bias was always absent. The most prevalent cytological category was AUS/FLUS (30%). Because the large majority of cases were classified as Bethesda III, IV or V, we considered these three classes for sub-analysis; the pooled rate of NIFTP with a presurgical cytology diagnosis in class III-IV was 52% (95% CI from 42 to 62), with heterogeneity (I² 88%, 95% CI from 82 to 91) and without publication bias (P = 0.32); the pooled rate of NIFTP with a cytology diagnosis in III-IV-V was 78% (95% CI from 71 to 84) with heterogeneity (I² 80%, 95% CI from 66 to 86) and no publication bias (P = 0.21). Subsequently, to resolve the heterogeneity between the studies, we analyzed the pooled results from those studies with a larger series of NIFTP; there were 7 studies with 50 or more cases reporting 729 NIFTP (4, 5, 13, 16, 18, 22, 23) and these articles were chosen for this sub-analysis. The pooled results were quite similar to those summarized above: non diagnostic FNAC 4%, benign 13%, AUS/FLUS 27%, FN/SFN

24%, suspicious for malignancy 22% and malignant 9%. There was mild heterogeneity in all these results, however publication bias was only present in non-diagnostic FNAC. In addition, the pooled prevalence of FNAC classified as III-IV was 51%, and the pooled prevalence of cases classified as III-IV-V was 74%.

Discussion

NIFTP is a recently described entity among thyroid tumors (3) which is considered to have an indolent behavior. Therefore, these cases are considered similar to low malignant potential lesions that need a simple lobectomy (without subsequent radioiodine therapy) and then clinical follow-up (3). Alternatively, performing a total thyroidectomy is also a consideration (24). Thus, detecting these tumors before surgery would have a significant impact for the management of patients in clinical practice. To date, while FNAC diagnosis is pivotal in identifying benign and malignant thyroid nodules, it does not have the ability to confidentially predict a NIFTP lesion. Several retrospective data have been reported, but there is no clear evidence that there is a way to predict the presence of a NIFTP cytologically (25). The present study was specifically undertaken to provide more robust information on the cytological TBSRTC categories associated with NIFTP in the currently available literature (references in Table 1). Fifteen relevant studies were retrieved and 915 cases of NIFTP were described in these papers. The most important result was that, using FNAC, three in four NIFTP were read as AUS/FLUS or FN/SFN (Figure 2) or SM, only 8% were classified as malignant, and a non-negligible number of cases were cytologically benign (10%) or not adequate for diagnosis (3%). These findings were confirmed when meta-analysis was performed only on those papers with a larger series of cases.

First and foremost, the introduction of the NIFTP concept has perturbed the cytopathology community. The low malignant potential of resected encapsulated, non-invasive E-FV-PTC, has been known for years. The change in name (with the disappearance of the term, “carcinoma”) and the downgrading of this entity to a low potential malignant lesion that requires simple lobectomy, has prompted cytopathologists to investigate whether this tumor might be detected in FNAC samples in order to guide the subsequent surgical treatment and tailor the management of patients. As shown in our study, a significant

proportion of NIFTP was classified as cytologically indeterminate into the AUS/FLUS DC. AUS/FLUS DC is a problematic and heterogeneous category, comprising cases that present diagnostic difficulties due to poorly preserved, poorly fixed or poorly stained specimens (26) or comprising paucicellular specimens with mild atypia, either architectural (microfollicular structures) or cytological (nuclear atypia), that are qualitatively and quantitatively insufficient to place the FNAC either into the FN/SFN DC or in the SM or M diagnostic categories (26). The incidence of cases placed into the AUS/FLUS category should not be superior to 10% according to the new version of TBSRTC in order to maintain a high diagnostic accuracy of thyroid FNAC. However, as shown by our study in which NIFTP lesions were found to be most commonly associated with AUS/FLUS diagnoses, we assume that there may be an increase in AUS/FLUS cases in the future, which may be higher than the recommended 10% (1). Moreover, since NIFTP is ultimately a histological diagnosis and hence a surgical disease, limited surgery (lobectomy) is recommended for these cases to confirm the cytological suspicion. In the USA, pre-surgical triage can also be done by carrying out molecular tests for indeterminate FNA results, thus refining the role of cytology. However, the fact that the majority of NIFTP cases in our meta-analysis (30%) are placed in to the AUS/FLUS DC, reflects the diagnostic difficulties related to NIFTP: since atypical nuclear changes in NIFTP are subtle (beyond that of a benign aspirate but insufficient to warrant a suspicious for malignancy diagnosis), most cases fall in this category, as suggested also by Strickland et al. (1, 2, 8). In addition, according to our present study, a non-negligible rate of NIFTP were cytologically classified as benign (10%). Unfortunately, we do not know if the benign diagnoses were due to the cytopathologist missing slight nuclear atypia or whether they were not missed but considered to be of reactive nature, or whether there was a problem related to the sampling (i.e. normal thyroid instead of the lesion). Since NIFTP are lesions of low malignant potential, these missed diagnoses would probably not have any impact on quality of life of these patients, but a long follow-up is needed to confirm this assumption. Eight percent of all reported NIFTP cases were diagnosed as malignant. Considering that the 2015 ATA guidelines suggests both lobectomy and total thyroidectomy as treatment options for low-risk PTC, there should not be any important medico-legal issues related to this “false positive” diagnosis (24, 25).

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Undoubtedly, awareness of the NIFTP and the vast number of articles that have been written concerning the cytopathological features of the NIFTP, suggest that, on routine cytology, this entity had an impact on cytopathologists, who now pay more attention (at least the authors of the present paper) to subtle nuclear atypias. In the future, as data on prospective evaluations of cytology findings and NIFTP histologies become available, cytopathologists may place less cases into the SM and M categories (reserved only for very suspicious or clear cut cases of PTC, as suggested by the revised version of TBSRTC), but this will result in an increase in AUS/FLUS diagnoses (1). When dealing with nuclear atypia, cytopathologists have the possibility of a NIFTP in mind and they would like to avoid a false positive diagnosis. This perspective change will also affect the manner in which NIFTP will be diagnosed in the future. In our opinion, a diagnosis of “malignant” by cytology will be reduced in frequency, as only clear-cut cases of PTC will be cytologically classified (9).

Limitations and strengths of the present review have to be discussed. Almost all studies included in the review were retrospective and the authors reviewed FNAC samples of NIFTP specifically for the publications; this study design could introduce a bias. We found that NIFTP may be associated with all cytological categories (from I to VI of TBSRTC). Therefore, we must consider that there is a selection bias in almost all included studies because NIFTP was searched for at histology and some other cases whose lesion was cytologically classified as non-diagnostic, benign or indeterminate by FNAC may not have undergone surgery. Consequently, the incidence of NIFTP cytologically classified as Bethesda I to IV might be higher than we found; on the contrary, the percentage of NIFTP read as malignant, when using FNAC, could be overestimated. As further evidence, this finding was present particularly in those articles with a small sample size.

In conclusion, the present meta-analysis shows that the diagnosis of NIFTP by FNAC remains a significant challenge. In fact, the majority of these cases are cytologically assessed as indeterminate and the others may be read as non-diagnostic, benign or malignant. Further cytological investigations are needed in order to develop a tailored management of these cases.

Author Disclosure Statement

The authors have nothing to disclose.

Corresponding author:

Massimo Bongiovanni, MD

Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology,
Lausanne, Switzerland

E-mail: massimo.bongiovanni@chuv.ch

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

References

1. Ali SZ, Cibas ES 2017 The Bethesda System for Reporting Thyroid Cytopathology. Definitions, Criteria, and Explanatory Notes. 2nd edition. ed. Wiley, New York.
2. Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, Chandra A, Cochand-Priollet B, Fadda G, Hirokawa M, Hong S, Kakudo K, Krane JF, Nayar R, Parangi S, Schmitt F, Faquin WC 2016 The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel. *Acta Cytol* **60**:399-405.
3. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nose V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA 2016 Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. *JAMA oncology* **2**:1023-1029.
4. Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW 2016 Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. *Cancer Cytopathol* **124**:181-187.
5. Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA 2015 The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories. *Thyroid* **25**:987-992.
6. Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M 2016 Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology. *Hum Pathol* **54**:134-142.

7. DerSimonian R, Laird N 1986 Meta-analysis in clinical trials. *Controlled clinical trials* **7**:177-188.
8. Strickland KC, Howitt BE, Barletta JA, Cibas ES, Krane JF 2018 Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules. *Cancer Cytopathol* **126**:86-93.
9. Ohori NP, Wolfe J, Carty SE, Yip L, LeBeau SO, Berg AN, Schoedel KE, Nikiforov YE, Seethala RR 2017 The influence of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) resection diagnosis on the false-positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria. *Cancer Cytopathol* **125**:692-700.
10. Brandler TC, Zhou F, Liu CZ, Cho M, Lau RP, Simsir A, Patel KN, Sun W 2017 Can noninvasive follicular thyroid neoplasm with papillary-like nuclear features be distinguished from classic papillary thyroid carcinoma and follicular adenomas by fine-needle aspiration? *Cancer Cytopathol* **125**:378-388.
11. Hahn SY, Shin JH, Lim HK, Jung SL, Oh YL, Choi IH, Jung CK. 2017 Preoperative differentiation between noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and non-NIFTP. *Clin Endocrinol (Oxf)*. 86:444-450.
12. Strickland KC, Vivero M, Jo VY, Lowe AC, Hollowell M, Qian X, Wiczorek TJ, French CA, Teot LA, Sadow PM, Alexander EK, Cibas ES, Barletta JA, Krane JF 2016 Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective Analysis. *Thyroid* **26**:1466-1471.
13. Canberk S, Gunes P, Onenerk M, Erkan M, Kilinc E, Kocak Gursan N, Kilicoglu GZ 2016 New Concept of the Encapsulated Follicular Variant of Papillary Thyroid Carcinoma and Its Impact on the Bethesda System for Reporting Thyroid Cytopathology: A Single-Institute Experience. *Acta Cytol* **60**:198-204.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

14. Ibrahim AA, Wu HH 2016 Fine-Needle Aspiration Cytology of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma Is Cytomorphologically Distinct From the Invasive Counterpart. *Am J Clin Pathol* **146**:373-377.
15. Bizzarro T, Martini M, Capodimonti S, Straccia P, Lombardi CP, Pontecorvi A, Larocca LM, Rossi ED 2016 Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification. *Cancer Cytopathol* **124**:699-710.
16. Zhao L, Dias-Santagata D, Sadow PM, Faquin WC 2017 Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma. *Cancer Cytopathol* **125**:323-331.
17. Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF 2017 A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience. *Cancer Cytopathol* **125**:854-864.
18. Bychkov A, Keelawat S, Agarwal S, Jain D, Jung CK, Hong S, Lai CR, Satoh S, Kakudo K 2018 Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries. *Pathology* **50**:411-417.
19. Diaz Del Arco C, Fernandez Acenero MJ 2018 Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Can Cytology Face the Challenge of Diagnosis in the Light of the New Classification? *Acta Cytol*:1-8.
20. Mahajan S, Agarwal S, Kocheri N, Jain D, Mathur SR, Iyer VK 2018 Cytopathology of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A comparative study with similar patterned papillary thyroid carcinoma variants. *Cytopathology* **29**:233-240.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

21. Kim M, Kim JE, Kim HJ, Chung YR, Kwak Y, Park SY 2018 Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features and Its Impact on the Risk of Malignancy in the Bethesda System for Reporting Thyroid Cytopathology: An Institutional Experience. *J Pathol Transl Med* **52**:171-178.
22. Mainthia R, Wachtel H, Chen Y, Mort E, Parangi S, Sadow PM, Lubitz CC 2018 Evaluating the projected surgical impact of reclassifying noninvasive encapsulated follicular variant of papillary thyroid cancer as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. *Surgery* **163**:60-65.
23. Lastra RR, Birdsong G, Hwang DH, Jorda M, Kerr DA, McGrath C, Odronic S, Rao R, VanderLaan PA, Walker JW, Antic T 2018 Preoperative cytologic interpretation of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a 1-year multi-institutional experience. *Journal of the American Society of Cytopathology* **7**:79-85.
24. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L 2016 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **26**:1-133.
25. Hung YP, Barletta JA 2018 A user's guide to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). *Histopathology* **72**:53-69.
26. Bongiovanni M, Krane JF, Cibas ES, Faquin WC 2012 The atypical thyroid fine-needle aspiration: past, present, and future. *Cancer Cytopathol* **120**:73-86.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Table 1. Main characteristics of the included studies.

First author [ref]	Year	Journal	Country	Single/multi-institute study	FNAC classification of cases	NIF TP cases (n)
<u>Strickland [5]</u>	<u>2015</u>	<u>Thyroid</u>	<u>USA</u>	<u>Single</u>	<u>During clinical practice</u>	<u>85</u>
Canberk [13]	2016	Acta Cytol	Turkey	Single	Retrospective	94
Strickland [12]	2016	Thyroid	USA	Single	During clinical practice	8
Ibrahim [14]	2016	Am J Clin Pathol	USA	Single	Retrospective	23
Bizzarro [15]	2016	Cancer Cytopatol	Italy	Single	Retrospective	37
Faquin [4]	2016	Cancer Cytopatol	USA, Switzerland	Multi	Retrospective	173
Zhao [16]	2017	Cancer Cytopatol	USA	Single	Retrospective	50
Hahn [11]	2017	Clin Endocrinol	Korea	Multi	Retrospective	35
<u>Mito [17]</u>	<u>2017</u>	<u>Cancer Cytopatol</u>	<u>USA</u>	<u>Single</u>	<u>Retrospective</u>	<u>29</u>

Thyroid
Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Bychkov [18]	20 18	Pathology	Thailand, India, Taiwan, Japan Korea	Multi	Retrospective	59	18
Diaz del Arco [19]	20 18	Acta Cytol	Spain	Single	Retrospective	6	
Mahajan [20]	20 18	Cytopathol	India	Single	Retrospective	23	
Kim [21]	20 18	J Pathol Transl Med	Korea	Single	Retrospective	25	
Mainthia [22]	20 18	Surgery	USA	Single	Retrospective	149	
Lastra [23]	20 18	JASC	USA	Multi	During clinical practice	119	
TOT						915	

Legend – All data refer to NIFTP with a proven histological diagnosis. All studies reported conventional cytological examinations of smears except two studies [5,15] which used liquid-based cytology.

Table 2. Quality assessment of the studies according to QUADAS-2.

First author [ref]	Risk of bias				Feasibility		
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Strickland [5]	L	L	L	L	L	L	L
Canberk [13]	L	H	L	H	L	L	L
<u>Strickland [12]</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>
Ibrahim [14]	L	U	L	L	L	L	L
Bizzarro [15]	L	H	L	H	L	L	L
Faquin [4]	L	L	L	L	L	L	L
Zhao [16]	L	H	L	H	L	L	L
Hahn [11]	L	H	L	H	L	L	L
<u>Mito [17]</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>	<u>L</u>
Bychkov [18]	L	H	L	H	L	L	L
Diaz del Arco [19]	L	H	L	H	L	L	L
Mahajan [20]	L	L	L	L	L	L	L
Kim [21]	L	H	L	H	L	L	L
Mainthia [22]	L	H	L	H	L	L	L
Lastra [23]	L	L	L	L	L	L	L

Legend – L, low risk of bias; H, high risk of bias, U, unclear risk of bias.

Table 3. Proportion of NIFTP in the cytological classes of Bethesda system.

Bethesda category	Pooled rate (95% CI)	Consistency – I2 (95% CI)	Publication bias
Non diagnostic	<u>3%</u> (2 to 6)	<u>62%</u> (23 to 67)	<u>P = 0.08</u>
Benign	<u>10%</u> (7 to 14)	<u>69%</u> (41 to 81)	<u>P = 0.27</u>
AUS/FLUS	<u>30%</u> (23 to 38)	<u>81%</u> (68 to 87)	<u>P = 0.41</u>
FN/SFN	<u>21%</u> (16 to 27)	<u>71%</u> (45 to 82)	<u>P = 0.92</u>
Suspicious for malignancy	<u>24%</u> (18 to 31)	<u>79%</u> (64 to 86)	<u>P = 0.07</u>
Malignant	<u>8%</u> (5 to 11)	<u>57%</u> (11 to 75)	<u>P = 0.11</u>

Legend – Absence of heterogeneity was set at I2 <50%. Publication bias was analysed using the Egger test: a significant test identified the presence of publication bias.




Fig 1. Forest plot of the pooled rate (95% CI) of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) in the six diagnostic categories of the Bethesda system (random effect).

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.




Fig 2. Cytohistological correlation in a case of NIFTP in a 35-year old female with a 2.2 cm nodule evaluated by ultrasound-guided thyroid fine-needle aspiration. (A) Clusters of microfollicular structures presented nuclear superposition, enlargement and scattered grooves (arrows) (Liquid-based cytological specimen, Papanicolaou staining, 400x). The final cytopathological diagnosis was that of follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN). (B) Grossly, the nodule showed a whitish appearance and was well circumscribed and (C) did not show microscopic signs of capsular or vascular invasion. It was predominantly comprised of microfollicular structures mixed with more cystic follicles (asterisks), at high power magnification atypical nuclei were evident (clearing of the chromatin) and only a single nuclear pseudoinclusion (arrow) was detected. The final histopathological diagnosis was that of NIFTP.

Supplementary Table 1. PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4

Thyroid
Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)
This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	5

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5-6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	5-6
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	5-6
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	5-6
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	5-6
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	5-6

Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	NA
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	6-9
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	8
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	9
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	None


From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Thyroid

Cytological diagnoses associated with non-invasive follicular thyroid neoplasms with papillary-like nuclear features, (NIFTP) according to the Bethesda System for Reporting Thyroid Cytopathology: a systematic review and meta-analysis. (DOI: 10.1089/thy.2018.0394)

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.



Supplementary Figure 1 : Flow chart of the search for eligible studies.